Clinical trials: Cancer of the Fallopian Tube
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
This is a Phase 1 study during which patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer will receive investigational study drug MEK162 and paclitaxel.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT01649336
- Testing
- MEK162, MEK inhibitor; oral, Paclitaxel, mitotic inhibitor; intravenous
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Cervical Cancer, Endometrial Cancer
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
RATIONALE: To improve strategies for detection and prevention of early-stage disease. PURPOSE: This research study is collecting specimens and data to develop better methods for early detection and prevention of ovarian cancer…
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
- Trial name
- NCT00005095
- Testing
- Ca-125, screening questionnaire administration, Surgery
- Where
- United States
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Ovarian Cancer
A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer
This is a multicenter， open-label study to evluate the efficacy and safety of a novel PARP 1/2 inhibitor fluzoparib （SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer.
- Trial name
- NCT03509636
- Testing
- Fluzoparib
- Where
- China
- Volunteers
- 113 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Ovarian Cancer Recurrent
DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer
The purpose of this trial is to investigate if maintenance DCVAC/OvCa after second-line chemotherapy of carboplatin/gemcitabine or carboplatin/paclitaxel improves efficacy outcomes in women with FIGO stage III and IV epithelial…
- Trial name
- NCT03657966
- Testing
- DCVAC/OvCa, Standard of Care Chemotherapy
- Where
- 8 sites in Czechia
- Volunteers
- 33 people
- Sponsor
- SOTIO a.s.
Cancer-related Cognitive Dysfunction, Cytomegaloviral Infection
Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment
This study evaluates the feasibility and accuracy of using saliva to remotely monitor cytomegalovirus (CMV) infection in individuals receiving treatment for ovarian cancer.
- Conditions
- Cancer-related Cognitive Dysfunction, Cytomegaloviral Infection, Fallopian Tube Carcinoma, Ovarian Carcinoma
- Trial name
- NCT06870539
- Testing
- Non-Interventional Study
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- Mayo Clinic
Endometrial Cancer, Fallopian Tube Cancer
Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive
The purpose of this study is to determine whether narrowband imaging (NBI) makes it easier for a surgeon to see cancer. NBI is a kind of light. Normally, white light is used during surgery.
- Conditions
- Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- Trial name
- NCT01262040
- Testing
- Narrow Band Imaging (NBI)
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer, Peritoneal Cancer
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary…
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- GLORIOSA (NCT05445778)
- Testing
- Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab
- Where
- 264 sites in United States, Argentina and 20 more
- Volunteers
- 520 people
- Sponsor
- AbbVie
Brenner Tumor, Fallopian Tube Cancer
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
This phase I trial is studying the side effects and best dose of intraperitoneal infusions of carboplatin when given together with intravenous infusions of either docetaxel or paclitaxel followed by intraperitoneal paclitaxel in…
- Conditions
- Brenner Tumor, Fallopian Tube Cancer, Ovarian Carcinosarcoma, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT00085358
- Testing
- carboplatin, paclitaxel, docetaxel
- Where
- 16 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer
Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00004064
- Testing
- oregovomab
- Where
- 16 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- AltaRex
Polycystic Ovary Syndrome
Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS)
PolysCsytic Ovaries Syndrome (PCOS) is the most frequent endocrinopathy. The first stage of infertility treatment is Clomiphene Citrate which leads to 50 % pregnancies.
- Trial name
- PERCING (NCT00378729)
- Testing
- Metformin and FSHr, Ovarian drilling by FERTILOSCOPY
- Where
- France
- Volunteers
- 252 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ovarian Epithelial Cancer Recurrent, Fallopian Tube Carcinoma
Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?
The purpose of this study is to evaluate the role of secondary cytoreduction (SCR) and validate the risk model of patient selection criteria in platinum-sensitive recurrent ovarian cancer.
- Conditions
- Ovarian Epithelial Cancer Recurrent, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT01611766
- Testing
- Secondary Cytoreductive Surgery, Salvage Chemotherapy
- Where
- 4 sites in China
- Volunteers
- 356 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Solid Tumor, Clear Cell Renal Cell Carcinoma
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
This is a first-in-human open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610 given by intravenous infusion in patients with…
- Conditions
- Solid Tumor, Clear Cell Renal Cell Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- NCT05199272
- Testing
- 23ME-00610
- Where
- 13 sites in United States, Canada
- Volunteers
- 141 people
- Sponsor
- 23andMe, Inc.
Ovarian Cancer, Peritoneal Cancer
Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers
PICCOLO (IMGN853-0419) is a Phase 2 multicenter, open label study designed to evaluate the safety and efficacy of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube…
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- PICCOLO (NCT05041257)
- Testing
- Mirvetuximab soravtansine
- Where
- 35 sites in United States, Australia and 5 more
- Volunteers
- 79 people
- Sponsor
- AbbVie
Fallopian Tube Cancer, Ovarian Cancer
Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: A phase I trial to study the side effects of vaccine therapy in patients with ovarian epithelial, primary peritoneal, or fallopian tube…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00066729
- Testing
- NY-ESO-1 peptide vaccine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Ludwig Institute for Cancer Research
Ovarian Cancer, Fallopian Tube Cancer
WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer
This is an open-label, pilot study in patients with a diagnosis of recurrent ovarian, fallopian tube or primary peritoneal carcinoma who have undergone standard cytoreductive surgery following by adjuvant chemotherapy.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
- Trial name
- NCT01144442
- Testing
- Hyperthermic intraperitoneal chemotherapy with Carboplatin, Isotonic saline (perfusate), Surgery
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Ovarian Cancer, Primary Peritoneal Cancer
Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
The purpose of this study is to test the safety of the drug olaparib at different dose levels. It will be given with the standard initial chemotherapy for cancer as well as a drug called bevacizumab.
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT02121990
- Testing
- Paclitaxel,, Bevacizumab, Cisplatin
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer
The purpose of this study is to evaluate the safety and the effectiveness of hepato-celiac lymphadenectomy in the treatment of primarily diagnosed advanced epithelial ovarian cancer and platinum-sensitive recurrent ovarian cancer.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT05236686
- Testing
- Hepato-celiac lymphadenectomy
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Borderline Ovarian Mucinous Tumor, Ovarian Mucinous Cystadenocarcinoma
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
This randomized phase III trial studies carboplatin given together with paclitaxel with or without bevacizumab to see how well it works compared with oxaliplatin given together with capecitabine with or without bevacizumab as…
- Conditions
- Borderline Ovarian Mucinous Tumor, Ovarian Mucinous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT01081262
- Testing
- Bevacizumab, Capecitabine, Carboplatin
- Where
- 248 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer
Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission
This partially randomized phase I/IIb trial studies the side effects vaccine therapy and indoleamine 2,3-dioxygenase (IDO1) inhibitor 4-amino-1,2,5-oxadizaole-3-carboximidamide (INCB024360) and to see how well they work in…
- Conditions
- Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IA Fallopian Tube Cancer
- Trial name
- NCT01982487
- Testing
- ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine, IDO1 inhibitor INCB024360, laboratory biomarker analysis
- Sponsor
- Roswell Park Cancer Institute
Platinum-resistant Ovarian Cancer
GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer
This phase 1 study evaluates the safety, efficacy, and biological activity of GB-5267 in patients with platinum-resistant ovarian cancer.
- Trial name
- NCT07489287
- Testing
- GB-5267 - IV only, GB-5267 -Combined IV and IP Infusion
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Roswell Park Cancer Institute